Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA clears Haemonetics' cell-washing capabilities:

This article was originally published in Clinica

Executive Summary

The US FDA has given Haemonetics' approval to broaden the use of its ACP 215 blood processing system to include a protocol for red blood cell washing. Previously cleared for freezing and thawing of red cells, the system can now allow doctors to remove more than 99% of plasma proteins from red blood cells derived from whole blood in a fully automated, closed system that supports good manufacturing practices, says the Braintree, Massachusetts firm. Plasma proteins can increase adverse patient reactions. The ACP 215 system reduces the labour involved with traditional red cell washing methods.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT063652

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel